Traws Pharma CFO granted new stock awards
Parker Charles Nolan reported acquisition or exercise transactions in this Form 4 filing.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Parker Charles Nolan reported acquisition or exercise transactions in this Form 4 filing.
Traws Pharma, Inc. Chief Financial Officer Parker Charles Nolan reported multiple equity awards from the company. He received 15,393 restricted stock units that vest 100% on the first anniversary of the grant date. He was also granted stock options for 104,544 shares at $1.60, 61,571 shares at $2.33, and 32,406 shares at $3.01 per share, each vesting in full one year after the respective grant dates.
Insider Trade Summary
Grant/Award: 213,914 shares
Grant/Award
4 txns
Insider
Parker Charles Nolan
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 104,544 | $0.00 | $0.00 |
| Grant/Award | Stock Option (right to buy) | 61,571 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 15,393 | $0.00 | $0.00 |
| Grant/Award | Stock Option (right to buy) | 32,406 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 198,521 contracts (Direct);
Common Stock — 15,393 shares (Direct)
Holdings Before and After:
Stock Option (right to buy), 0 to 198,521 contracts (Direct);
Common Stock, 0 to 15,393 shares (Direct)
Footnotes (4)
- F1. Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.
- F2. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
- F3. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
- F4. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
Key Figures
RSU grant: 15,393 units
Option grant 1: 104,544 shares at $1.60
Option grant 2: 61,571 shares at $2.33
+4 more
7 metrics
RSU grant
15,393 units
Restricted stock units vest 100% after one year
Option grant 1
104,544 shares at $1.60
Stock options, expire in 2036
Option grant 2
61,571 shares at $2.33
Stock options, expire in 2035
Option grant 3
32,406 shares at $3.01
Stock options, expire in 2035
Post-grant option position 104,544
104,544 derivative shares
Total shares following latest 1.60 option grant
Post-grant option position 61,571
61,571 derivative shares
Total shares following 2.33 option grant
Post-grant stock position
15,393 shares
Total common shares following RSU award
Key Terms
restricted stock units, stock options, 2021 Incentive Compensation Plan, expiration date
4 terms
restricted stock units financial
"Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock options financial
"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
2021 Incentive Compensation Plan financial
"under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof."
expiration date financial
"expiration_date": "2036-03-08T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Traws Pharma (TRAW) report for its CFO?
Traws Pharma’s CFO, Parker Charles Nolan, reported receiving equity awards. He was granted restricted stock units and several stock option awards, all as compensation. These transactions increase his potential ownership but do not involve any open-market buying or selling of TRAW shares.
How many restricted stock units did the Traws Pharma CFO receive?
Parker Charles Nolan received 15,393 restricted stock units. According to the disclosure, these units vest 100% on the first anniversary of the grant date, and each unit converts into one share of Traws Pharma common stock upon vesting, aligning his compensation with shareholder value.
What stock option grants did the Traws Pharma (TRAW) CFO receive and at what prices?
The CFO received stock options over 104,544 shares at $1.60, 61,571 shares at $2.33, and 32,406 shares at $3.01 per share. All options were granted at a zero-cost award price but have specified exercise prices if he chooses to purchase the underlying common shares later.
When do the new Traws Pharma CFO stock options expire?
The reported stock options have long-dated expirations. The 104,544-share grant at $1.60 expires in 2036, while the 61,571-share grant at $2.33 and the 32,406-share grant at $3.01 both expire in 2035, providing extended exercise windows for the CFO.
How do the equity awards to the Traws Pharma CFO vest?
Both the restricted stock units and the stock options vest 100% on the first anniversary of each grant date. This means the CFO must remain in position through that one-year period to receive the full benefit, supporting retention and long-term alignment with Traws Pharma shareholders.
Were the Traws Pharma CFO’s equity awards part of a company compensation plan?
Yes. The filing states the stock options were awarded under Traws Pharma’s 2021 Incentive Compensation Plan by the compensation committee of independent directors. This indicates the grants are structured compensation rather than discretionary market purchases of TRAW stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
